Health Care • Medical/Dental Instruments
$2.05 ▼ -0.24
(-10.48%)
MKT CAP: $6.2M • VOL: 172.5K
52W L $2 52W H $46
ROARABLE / RQD
E • 30/100
PIOTROSKI
5 / 9
TNON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.9M | $3.3M | $2.9M |
| YoY Revenue Growth % | +20.4% | +11.9% | — |
| Gross Profit | $2.4M | $1.7M | — |
| Gross Margin % | 59.8% | 52.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.8M | -$13.8M | -$15.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$12.6M | -$13.7M | -$15.6M |
| EBITDA (Normalized) | -$12.6M | -$13.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.7M | -$9.9M | -$12.2M |
| Capital Expenditures (CapEx) | $273.0K | $186.0K | — |
| Free Cash Flow (FCF) | -$11.0M | -$10.1M | -$12.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.8M | $6.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.0M | $6.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TNON.